Guangdong Hybribio Biotech Co.,Ltd. (SHE:300639)
China · Delayed Price · Currency is CNY 6.43
+0.08 (1.26%)
May 19, 2026, 10:25 AM CST
SHE:300639 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 661.41 | 669.64 | 806.72 | 1,075 | 5,519 | 2,647 |
Other Revenue | - | - | 8.81 | 29.75 | 78.35 | 26.43 |
| 661.41 | 669.64 | 815.53 | 1,104 | 5,597 | 2,673 | |
Revenue Growth (YoY) | -13.71% | -17.89% | -26.16% | -80.27% | 109.39% | 97.34% |
Cost of Revenue | 367.11 | 365.19 | 440.35 | 442.1 | 1,807 | 865.5 |
Gross Profit | 294.31 | 304.45 | 375.18 | 662.35 | 3,790 | 1,808 |
Selling, General & Admin | 374.41 | 373.38 | 482 | 532.48 | 847.68 | 581.7 |
Research & Development | 58.94 | 62.39 | 85.64 | 136.32 | 247.28 | 115.29 |
Other Operating Expenses | 5.57 | 5.07 | 10.81 | 9.93 | 21.3 | 12.88 |
Operating Expenses | 412.76 | 440.84 | 1,185 | 667.97 | 1,367 | 761.63 |
Operating Income | -118.45 | -136.39 | -810.23 | -5.62 | 2,424 | 1,046 |
Interest Expense | -2.91 | - | -1.58 | -4.94 | -8.18 | -7.4 |
Interest & Investment Income | - | - | 27.4 | 47.45 | 36.4 | 24.42 |
Currency Exchange Gain (Loss) | - | - | -20.95 | -15.89 | -2.36 | 0.86 |
Other Non Operating Income (Expenses) | 15.69 | -9.88 | -1.82 | -1.55 | -2.29 | -1.21 |
EBT Excluding Unusual Items | -105.67 | -146.27 | -807.19 | 19.44 | 2,447 | 1,063 |
Gain (Loss) on Sale of Investments | 4.32 | 3.85 | 4.05 | -0 | 0.04 | 0.14 |
Gain (Loss) on Sale of Assets | 0.14 | 0.43 | -0.25 | 7.06 | 4.34 | 2.34 |
Asset Writedown | -27.01 | -27.33 | -24.79 | 1.56 | -291.74 | -6.42 |
Other Unusual Items | - | - | -4.79 | 8.76 | -31.96 | -1.44 |
Pretax Income | -128.21 | -169.32 | -832.97 | 36.82 | 2,128 | 1,057 |
Income Tax Expense | 16.13 | 12.96 | 117.38 | -31.7 | 326.06 | 172.24 |
Earnings From Continuing Operations | -144.34 | -182.28 | -950.35 | 68.51 | 1,802 | 884.94 |
Minority Interest in Earnings | 37.91 | 51.34 | 295.47 | 71.96 | -75.81 | -32.78 |
Net Income | -106.43 | -130.94 | -654.88 | 140.47 | 1,726 | 852.16 |
Net Income to Common | -106.43 | -130.94 | -654.88 | 140.47 | 1,726 | 852.16 |
Net Income Growth | - | - | - | -91.86% | 102.54% | 134.97% |
Shares Outstanding (Basic) | 624 | 624 | 642 | - | 659 | 659 |
Shares Outstanding (Diluted) | 624 | 624 | 642 | - | 659 | 659 |
Shares Change (YoY) | 0.00% | -2.88% | - | - | -0.02% | 7.39% |
EPS (Basic) | -0.17 | -0.21 | -1.02 | - | 2.62 | 1.29 |
EPS (Diluted) | -0.17 | -0.21 | -1.02 | - | 2.62 | 1.29 |
EPS Growth | - | - | - | - | 102.58% | 118.80% |
Free Cash Flow | 225 | 249.21 | -69.55 | -65.72 | 574.85 | -9.73 |
Free Cash Flow Per Share | 0.36 | 0.40 | -0.11 | - | 0.87 | -0.01 |
Dividend Per Share | - | - | - | 0.065 | 0.233 | 0.155 |
Dividend Growth | - | - | - | -72.14% | 50.03% | 74.13% |
Gross Margin | 44.50% | 45.47% | 46.01% | 59.97% | 67.72% | 67.62% |
Operating Margin | -17.91% | -20.37% | -99.35% | -0.51% | 43.30% | 39.13% |
Profit Margin | -16.09% | -19.55% | -80.30% | 12.72% | 30.84% | 31.88% |
Free Cash Flow Margin | 34.02% | 37.22% | -8.53% | -5.95% | 10.27% | -0.36% |
EBITDA | 34.33 | 17.35 | -652.7 | 159.93 | 2,591 | 1,127 |
EBITDA Margin | 5.19% | 2.59% | -80.03% | 14.48% | 46.29% | 42.17% |
D&A For EBITDA | 152.78 | 153.73 | 157.54 | 165.55 | 167.29 | 81.33 |
EBIT | -118.45 | -136.39 | -810.23 | -5.62 | 2,424 | 1,046 |
EBIT Margin | -17.91% | -20.37% | -99.35% | -0.51% | 43.30% | 39.13% |
Effective Tax Rate | - | - | - | - | 15.32% | 16.29% |
Revenue as Reported | - | - | 815.53 | 1,104 | 5,597 | 2,673 |
Advertising Expenses | - | - | 14.31 | 24.2 | 36.3 | 29.35 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.